NASDAQ NMS - GLOBAL MARKET · ALGS

+2.64% · +$0.1400 · Vol 9.1K

Market closed · last close 4:00 PM ET · price as of 18:55:47 ET

Aligos Therapeutics Inc

Biotechnology

$5.45

Card

Relationship Map

Follow $ALGS

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ALGS by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measured

Stale score · Thu Oct 8 · completed session · 33h old · Scheduled each trading day · Markets closed · resumes Mon 9:30 ET · ALGS

Methodology

Fri Oct 9 snapshot unavailable for ALGS. Cause unavailable.

ALGS

Aligos Therapeutics Inc

Stale score · Thu Oct 8 · completed session · 33h old · Scheduled each trading day · Markets closed · resumes Mon 9:30 ET

65/100

Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100

Veridion Score

Upper range · MEDIUM confidence · 6 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: MEDIUM · 6 of 6 factors measured · Stale score · Thu Oct 8 · completed session · 33h old · Scheduled each trading day · Markets closed · resumes Mon 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is ALGS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move ALGS next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Oct 8
Score
Score moved +18
47/Middle range -> 65/Upper range
Veridion score historySource

About Aligos Therapeutics Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

2020

Employees

Country

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$5.27

Day high

$5.44

Day low

$5.27

Previous close

$5.31

52W high

$13.29

-59.01% from high

52W low

$4.08

15% of range

Market cap

$33.2M

EPS

$-7.3139

Beta

1.14

Shares out

6.2M

Volume

9.1K

0.20× rel vol

Avg volume

44.6K

VWAP

$5.35

Price history computed in-house

-1.62%

+2.25%

-17.67%

-42.21%

YTD

-41.52%

SMA 50 $5.89 · below

SMA 200 $6.57 · below

52W position 15%

ALGS overview

Veridion Score

Registered · 2026-10-08

6 of 6 factors measured

Latest receipt rows

No recent disclosure on file.

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around ALGS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

ALGS insider activity

Aligos Therapeutics Inc

90 days, by filing date. Snapshot as of 2026-10-10T02:42:12.144Z.

Score

Not evaluated

Pressure

Not evaluated

Transactions

Unavailable

Filings

Unavailable

Buys / sells

Unavailable

Net value

Not evaluated

Insiders

Unavailable

Cluster

Not covered: this ticker is outside our Form 4 ingest scope — we have not looked

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

Form 4 evidence state

Not covered: this ticker is outside our Form 4 ingest scope — we have not looked.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in ALGS

Congress tracker Open ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

ALGS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for ALGS in this window.

Lobbying spend

ALGS lobbying filings, year to date.

Registered lobbying filings matched to Aligos Therapeutics Inc.

$220.0K

Refresh interval: 12hSource: LDA disclosure filings

Labor Issues/Antitrust/Workplace

Filing

$80.0K

ALIGOS THERAPEUTICS INC.

WILMER CUTLER PICKERING HALE AND DORR LLP

Apr 16, 2026

Filing

$80.0K

ALIGOS THERAPEUTICS INC.

WILMER CUTLER PICKERING HALE AND DORR LLP

Jan 18, 2026

Filing

$60.0K

ALIGOS THERAPEUTICS INC.

WILMER CUTLER PICKERING HALE AND DORR LLP

Jul 18, 2026

Analyst ratings

Sovereign unlock shows live analyst consensus for ALGS.

Options

Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Methodology

No related ticker met the data requirements for this rail.

Follow $ALGS

Why is ALGS moving today?

What can move ALGS next.

ALGS overview

Related filings and maps

ALGS insider activity

ALGS contract awards, year to date.

ALGS lobbying filings, year to date.

Cross-references from this score page.

What can move ALGS next.

ALGS insider activity

Cross-references from this score page.